Last reviewed · How we verify
treatment withdrawal
Withdrawal treatment involves the use of medications to help manage withdrawal symptoms in individuals who are dependent on substances such as opioids, alcohol, or benzodiazepines.
Withdrawal treatment involves the use of medications to help manage withdrawal symptoms in individuals who are dependent on substances such as opioids, alcohol, or benzodiazepines. Used for Management of opioid withdrawal symptoms, Prevention of opioid relapse.
At a glance
| Generic name | treatment withdrawal |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | opioid antagonist |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Withdrawal treatment typically involves a combination of medications and behavioral therapies to help manage symptoms such as anxiety, insomnia, and cravings. Medications such as buprenorphine, methadone, and naltrexone are commonly used to help manage withdrawal symptoms and prevent relapse.
Approved indications
- Management of opioid withdrawal symptoms
- Prevention of opioid relapse
Common side effects
- Nausea
- Headache
- Insomnia
- Anxiety
Key clinical trials
- Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (PHASE2)
- Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (PHASE2)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation (PHASE2)
- Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer (PHASE2)
- Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder (PHASE2)
- TheraSphere With Durvalumab and Tremelimumab for HCC (PHASE2)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment withdrawal CI brief — competitive landscape report
- treatment withdrawal updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI